The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.
Buthionine sulphoximide (BSO)-induced depletion of glutathione (GSH) was found to be associated with an increased sensitivity to CPT-11 (topoisomerase I-reactive agent) in V79 hamster lung fibroblast cells. When V79 cells were exposed to 2.5 mM BSO for 28 h beginning 4 h prior to a 24 h coincubation with CPT-11, cytotoxicity was increased compared with CPT-11 alone. It was determined that BSO resulted in a G1 cell cycle arrest and a decrease in the percentage of cells in S-phase. Since CPT-11 is known to be S-phase-specific, this BSO-induced cell cycle redistribution did not appear to account for the chemosensitisation of CPT-11. Additionally, BSO did not alter intracellular accumulation of CPT-11, conversion of CPT-11 to its active metabolite SN-38, or efflux of either CPT-11 or SN-38 from the cell. Finally, BSO resulted in a slight reduction, rather than an increase, in the number of stabilised DNA-topoisomerase I complexes induced by CPT-11. Therefore, these results suggest that BSO-induced sensitisation of V79 cells to the cytotoxic effects of CPT-11 occurs by a mechanism independent of the stabilisation of DNA-topoisomerase I complexes.
Sawyer
T E
TE
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Bonner
J A
JA
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D019328:Buthionine Sulfoximine / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D006224:Cricetinae; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005978:Glutathione / Q000032:analysis; D000077146:Irinotecan; D059004:Topoisomerase I Inhibitors
D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D019328:Buthionine Sulfoximine; D000077146:Irinotecan; D005978:Glutathione; D002166:Camptothecin